Mounjaro for Type 2 Diabetes: What the Clinical Evidence Shows

What the SURPASS trials found about tirzepatide and type 2 diabetes

The evidence base for Mounjaro in type 2 diabetes comes primarily from the SURPASS clinical programme, a series of phase 3 trials involving thousands of adults with type 2 diabetes across different treatment backgrounds. NICE's technology appraisal of tirzepatide reviewed this data in detail. SURPASS-2 is particularly relevant: it compared tirzepatide at 5mg, 10mg and 15mg directly against semaglutide 1mg (weekly injection) over 40 weeks. All three tirzepatide doses reduced HbA1c more than semaglutide did, and produced greater average weight loss. At 15mg, average body weight fell by around 13%, meaningful in a population where excess weight typically worsens blood-sugar control.

A question our prescribers hear most weeks is whether Mounjaro is simply a weight-loss drug being repurposed. It is not. Its mechanism (activating both GIP and GLP-1 receptors) was studied in diabetes populations first. The blood-sugar and weight effects are built into the same pharmacology. More detail on tirzepatide's mechanism in diabetes covers how that dual action differs from older GLP-1 medicines.

What the trials also show is that results vary. Participants who were insulin-naive tended to see larger HbA1c reductions than those already using basal insulin. Your starting HbA1c, renal function, other medicines and how long you have had diabetes all shape what you might reasonably expect. The trial averages are a reference point, not a forecast.

Which adults with type 2 diabetes may be eligible for Mounjaro

Mounjaro's UK licence for type 2 diabetes covers adults whose blood-sugar control is inadequate on existing treatment, used alongside diet and physical activity. The prescriber's decision goes well beyond a single criterion. Whether Mounjaro suits your particular diabetes picture depends on factors including current HbA1c, kidney function (eGFR), body weight, cardiovascular risk and what you already take.

Certain medical histories mean Mounjaro is not appropriate regardless of HbA1c. A personal or family history of medullary thyroid carcinoma, or a condition called Multiple Endocrine Neoplasia type 2, are contraindications. A history of pancreatitis requires careful discussion with a specialist. The NHS medicines page for tirzepatide on NHS.uk lists the full contraindication and caution profile in plain language.

For many people with type 2 diabetes, the NHS route through a GP or diabetes specialist will be most appropriate, particularly where complex medicines are already in play. Private routes (such as through a regulated online pharmacy) are available for weight management but the prescriber still needs to assess your diabetes management as part of that picture. If you would like a fuller picture of how Mounjaro is used for type 2 diabetes, including what the prescribing process involves, that page covers it in detail. No legitimate prescriber will ignore an existing diagnosis of type 2 diabetes when reviewing your consultation.

Managing other diabetes medicines alongside Mounjaro

This is where clinical oversight matters most. Tirzepatide lowers blood glucose effectively, and if you already take a sulphonylurea (such as gliclazide) or insulin, adding Mounjaro can increase the risk of hypoglycaemia. NHS England's guidance on weight-management injections explicitly notes that dose reductions of sulphonylureas or insulin may be needed when starting GLP-1 or dual-agonist medicines.

Metformin is generally continued alongside tirzepatide, the combination is common and does not raise the same low-blood-sugar concern. SGLT-2 inhibitors (such as dapagliflozin or empagliflozin) are also frequently used alongside GLP-1 class medicines in clinical practice, though your prescriber will confirm what applies to you.

Alcohol is worth raising, too. It can mask hypoglycaemia symptoms and interact with blood-sugar control in unpredictable ways when you are on diabetes treatment; the question of alcohol and Mounjaro is covered in more detail separately. The honest short answer is that moderate, occasional alcohol is generally low risk for most people, but your prescriber's view comes first.

Pregnancy, contraception and important safety considerations

Mounjaro is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. Animal studies raised concerns, and there is insufficient human safety data to establish that it is safe in these situations. If you are a person with type 2 diabetes and child-bearing potential, you should use effective contraception while on Mounjaro. What happens if you become pregnant on Mounjaro explains what current guidance says and what steps to take.

There is a specific practicality worth knowing. Because tirzepatide slows gastric emptying, it can reduce how much of an oral contraceptive pill is absorbed, particularly in the first four weeks of treatment and for four weeks after each dose increase. Adding a barrier method during those windows is the current NHS recommendation. This applies specifically to tirzepatide, not equally to all GLP-1 medicines, so if you are switching from a different injectable treatment, check the interaction with your prescriber or GP.

The MHRA issued a Drug Safety Update in January 2026 reminding prescribers and patients about pancreatitis as a known but uncommon risk with GLP-1 class medicines. Severe, persistent stomach pain (especially pain that spreads towards the back) should prompt urgent medical attention, not a wait-and-see approach. A separate consideration that sometimes arises is whether Mounjaro is appropriate where type 1 diabetes is present, and that page sets out the current clinical position clearly. Report any suspected side effects through the MHRA's Yellow Card scheme.

If you have questions about how Mounjaro might fit your diabetes management, speaking to a GPhC-registered prescriber is the right starting point. Our clinical team reviews every consultation personally. You can also start your free consultation to discuss your situation, clinical suitability is assessed on the day, individually.